Aims and objectives
Aim of this study was to establish the feasibility of performing percutaneous biopsy of lung lesions guided by fusion PET/CT-CBCT and to evaluate whether the metabolic informations provided by a prior PET/CT scan add incremental benefits for diagnosis.
Methods and materials
We retrospectively reviewed the data of 180 patients who underwent CBCT guided lung biopsy (90) and PET/CT-CBCT guided lung biopsy (90). Rates of diagnostic efficacy,
positive predictive value (PPV) and negative predictive value (NPV) were calculated. Furthermore,
for the patients with malignant lesions who underwent surgical resection,
we evaluated the histological agreement between the results of biopsy and surgery. For the patients with...
Diagnostic efficacy was equal to 93,3% (6/90 nondiagnostic) for the first group and 98,9% (1/90 nondiagnostic) for the second group,
with a statistically significant difference between the two groups (p=0,049). The values of sensitivity,
PPV and NPV were respectively 94,5%,
100% and 73,3% for the CBCT guided biopsies and 98,6%,
100% and 94,4% for the PET/CT-CBCT guided biopsies,
without any statistically significant difference...
PET/CT-CBCT guided lung biopsy is feasible and safe as well as CBCT guided biopsy. It can improve diagnostic efficacy’s value,
reducing the number of nondiagnostic samples and false negative (FN) cases and can be used to obtain more helpful informations from tissue sampling.
CIRSE Guidelines on Percutaneous Needle Biopsy (PNB).
Cardiovasc Intervent Radiol.
2017 Oct;40(10):1501–13. El-Haddad G.
PET-Based Percutaneous Needle Biopsy.
2016 Jul;11(3):333–49. Abi-Jaoudeh N,
Cone-Beam Computed Tomography Fusion and Navigation for Real-Time Positron Emission Tomography–guided Biopsies and Ablations: A Feasibility Study.
J Vasc Interv...